Saturday 17 October 2026
Export RNAZ’s income statement to Excel — free account
TransCode Therapeutics Inc.
RNAZ Healthcare Biotechnology
In the quarter to June 2026, EPS fell 39.8% and free cash flow fell 28.8%, each against the same quarter a year earlier.
1.70
0.10
−5.56%
Follow RNAZ
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 1,737,120.00 | 207,715.20 | 5,248.32 | 89.88 | 6.08 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 5,174,400.00 | 2,313,696.00 | 790,944.00 | 6,652.80 | 468.44 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 6 | 9 | 19 | 10 | 7 | 12 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (1) | (2) | (7) | (18) | (19) | (17) | (34) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (1) | (2) | (7) | (18) | (19) | (17) | (35) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 1 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.94) | (0.51) | (0.81) | (998,419.10) | (95,783.52) | (1,320.45) | (52.59) | |||||
| Cash flow | — | — | — | (0.79) | (0.11) | (0.63) | 0.00 | (90,372.50) | (1,058.41) | (28.30) | |||||
| Capex | — | — | — | 0.00 | 0.00 | (0.03) | 0.00 | (178.00) | (1.73) | (0.01) | |||||
| Free cash flow | — | — | — | (0.79) | (0.11) | (0.65) | 0.00 | (90,550.50) | (1,060.14) | (28.31) | |||||
| Book value | — | — | — | (1.70) | (0.74) | 2.42 | 0.00 | 8,204.00 | (160.21) | 14.99 | |||||
| Shares, m | — | — | — | 1 | 5 | 8 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | 0 | (5) | (16) | (18) | (13) | (20) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (1) | 0 | (6) | (16) | (18) | (13) | (20) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 0 | 20 | 3 | 1 | 4 | 18 | ||||
| Total debt | — | — | — | 1 | 2 | — | — | — | — | — | |||||
| Net debt | — | — | — | 1 | 1 | (21) | (5) | (3) | (6) | (18) | |||||
| Shareholders’ equity | — | — | — | (1) | (3) | 20 | 3 | 2 | (2) | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (560.41) | (368.51) | (57.04) | (115.08) | (290.74) | (269.34) | (42.75) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 27.03 | 104.04 | (80.53) | (148.57) | (759.85) | 8,883.62 | (872.24) | |||||
Negative figures in brackets.
Charts ten years each
TransCode Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| BCTX BRIACELL THERAP | $32.8M | 1.5× | — | — | n/m | +0.21% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.3M | — | — | — | — | +35.94% (above 0%: growing) | 0.00% | — | Compare |
| MGX Metagenomi Therapeutics, Inc. | $31.9M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| GRDX GridAI Technologies Corp. | $31.8M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NXTC NextCure, Inc. | $31.5M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CVM Cel-Sci Corporation | $30.6M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $30.5M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | |
| Median of peers | $32.1M | — | — | +1,549.08% | — | −1.06% | 0.00% | 0.00% |
TransCode Therapeutics Inc. (RNAZ) key facts
- TransCode Therapeutics Inc. (RNAZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, RNAZ traded at $1.70, a market capitalization of $30.5 million.
- Return on equity was −872.2% and debt-to-equity 0.00.